Alopecia Areata Treatment in Houston: JAK Inhibitors, Topicals, and What Actually Works in 2026

This article is educational and does not replace an evaluation by a board-certified dermatologist. If you are losing hair in patches, please book a visit.

Patients with alopecia areata usually arrive with two questions: why their hair is falling out in smooth, round patches, and whether the advertised pills, the oral JAK inhibitors, actually work. Alopecia areata is an immune condition, not something you did to your hair. Between 2022 and 2024 the FDA approved three oral JAK inhibitors for severe disease. They help many patients, not everyone, and they come with real safety tradeoffs. Here is where the evidence stands in 2026, and how a dermatologist decides what fits your situation.

What alopecia areata is (and what it is not)

The autoimmune mechanism

In alopecia areata, the immune system attacks the hair follicle and pushes it out of its growth phase. The follicle is not destroyed, which is why regrowth remains possible, sometimes years later. The American Academy of Dermatology (AAD) notes that it usually begins in children and young adults but can start at any age, affects people of every skin tone and gender, and can come and go. Hair may regrow on its own in about a year, but many people relapse within a year of regrowth (AAD).

The pattern varies. Most people have one or a few coin-shaped patches. Alopecia totalis means loss of all scalp hair. Alopecia universalis means loss of hair on the scalp and the rest of the body, which the AAD describes as rare. Eyebrows, eyelashes, beard hair, and nails can be involved.

How it differs from androgenetic alopecia

Androgenetic alopecia, better known as male and female pattern hair loss, is gradual thinning driven by genetics and hormones: a receding hairline and crown in men, a widening part in women. It does not produce sudden, smooth, round patches, and its treatments differ; our guide to PRP for hair loss in Houston covers that side of the spectrum.

How it differs from telogen effluvium and traction alopecia

Telogen effluvium is diffuse shedding all over the scalp, usually a few months after a trigger such as illness, surgery, childbirth, or rapid weight loss. Traction alopecia comes from tight hairstyles pulling on the follicles, usually along the hairline. Neither produces the sharply outlined patches of alopecia areata, but these conditions can overlap, and some scarring forms of hair loss look similar early on. If you are not sure whether your shedding is normal, start with our post on normal shedding versus hair loss.

Does hair dye cause alopecia areata?

Patients often ask this after noticing a patch soon after coloring their hair. There are no controlled studies showing that hair dye causes alopecia areata; the published link consists of individual case reports. What hair dye can do is different. Chemical processing weakens the hair shaft and causes breakage, and some people develop an allergic reaction to para-phenylenediamine (PPD), a common dye ingredient. In one published case, a woman lost about 90% of her scalp hair from allergic contact dermatitis to a PPD-containing dye, which improved with treatment (Ishida et al., 2011). That is a different diagnosis with a different treatment. Our post on whether hair dye can cause hair to fall out covers breakage in more detail.

How dermatologists diagnose alopecia areata

Scalp exam and dermoscopy findings

Most cases are diagnosed in the office. A dermatologist examines the patches and surrounding hair, often with a dermatoscope, a lighted handheld magnifier. Short broken hairs that taper toward the scalp (exclamation point hairs) support the diagnosis. Eyebrows, eyelashes, beard area, and nails are checked as well.

When we biopsy and when we do not

A scalp biopsy is not routine. It is considered when the picture is unclear, when scarring hair loss is a possibility, or when the hair loss is not responding as expected. Blood work may be ordered to look for related conditions, such as thyroid disease, or other causes of shedding (AAD).

SALT score and severity grading

Severity is measured with the Severity of Alopecia Tool, or SALT, which estimates the percentage of scalp hair missing on a scale of 0 to 100. A score of 100 means total scalp hair loss. The JAK inhibitor trials enrolled patients with at least 50% scalp hair loss and defined success as reaching a SALT score of 20 or lower, meaning at least 80% scalp coverage. Insurers often ask for this score, so documenting it at your first visit is useful.

Treatment decisions depend on your individual skin, medical history, and goals. The information below describes how dermatologists evaluate options; it is not a prescription or a recommendation for any specific person.

First-line treatments that are still first-line

Corticosteroid injections

For adults with a limited number of patches, injecting a corticosteroid such as triamcinolone directly into the bald spots is a standard first step. The AAD describes several small injections every 4 to 6 weeks, with regrowth usually appearing within about three months, and cites a study in which more than 80% of 127 patients with patchy hair loss had at least half their hair regrow within 12 weeks. Because the injections are uncomfortable, they are generally reserved for adults.

Topical corticosteroids and topical minoxidil

Corticosteroid creams, foams, or solutions applied once or twice daily are often used for children, in whom the AAD notes they tend to work better than in adults. Minoxidil does not calm the immune attack, but it can help maintain regrowth and is often added after other treatments. The AAD notes it needs to be applied two to three times a day to be effective for this purpose.

Contact immunotherapy for extensive disease

For widespread hair loss, a dermatologist may apply a chemical weekly to provoke a mild allergic rash on the scalp, which appears to redirect the immune response. The AAD reports success rates ranging from 17% to 75%, and missed appointments can cause the treatment to stop working. It requires weekly visits for months.

Oral JAK inhibitors: the 2022 to 2024 shift in severe disease

Janus kinase (JAK) inhibitors block signaling pathways that drive the immune attack on the follicle. All three approved options are daily pills carrying the same class boxed warning.

Baricitinib (Olumiant): the first FDA approval, June 2022

Baricitinib, which blocks JAK1 and JAK2, was approved on June 13, 2022 for adults with severe alopecia areata, becoming the first systemic treatment approved for the condition. The usual starting dose is 2 mg once daily, increased to 4 mg if the response is inadequate; for nearly complete or complete scalp loss, the label advises considering 4 mg from the start. In two placebo-controlled trials of 1,200 adults with at least 50% scalp loss, 32% to 35% of patients on 4 mg and 17% to 22% on 2 mg reached a SALT score of 20 or lower at week 36, compared with 3% to 5% on placebo. Response rates were lower in people with 95% or more scalp loss at baseline (21% on 4 mg) than in those with 50% to 94% loss (48% on 4 mg) (FDA label).

Ritlecitinib (Litfulo): approved 2023 for ages 12 and older

Ritlecitinib, which inhibits JAK3 and the TEC kinase family, was approved on June 23, 2023 for severe alopecia areata in adults and adolescents 12 years and older, making it the first option approved for teenagers. The dose is 50 mg once daily. In its pivotal trial, 23% of patients on 50 mg reached a SALT score of 20 or lower at week 24, compared with 1.6% on placebo. Nearly half of trial participants had alopecia totalis or universalis at baseline (FDA label).

Deuruxolitinib (Leqselvi): approved 2024 for adults

Deuruxolitinib, a JAK1 and JAK2 inhibitor, was approved in 2024 for adults with severe alopecia areata, at 8 mg twice daily. In two Phase 3 trials of 1,209 adults, 29% and 32% of patients on 8 mg reached a SALT score of 20 or lower at week 24, compared with 1% on placebo. Before starting, patients must be tested for CYP2C9 genotype: the drug is contraindicated in people who are CYP2C9 poor metabolizers and in those taking moderate or strong CYP2C9 inhibitors, because drug levels rise and so does the risk of serious side effects (FDA label).

How we choose among the three

There are no head-to-head trials, and the studies used different timepoints and populations, so their numbers cannot be compared directly. In practice, the choice comes down to age (only ritlecitinib is approved for adolescents), dosing preference (once versus twice daily), other medications you take, genetic testing results for deuruxolitinib, laboratory findings, and what your insurance plan covers.

Monitoring, side effects, and the boxed warning

Each label carries an FDA boxed warning for serious infections, mortality, malignancy, major adverse cardiovascular events (MACE), and thrombosis. Much of that warning comes from a large study of another JAK inhibitor in older rheumatoid arthritis patients, where risks were higher, particularly in current or past smokers and people with cardiovascular risk factors. Before treatment, patients are screened for tuberculosis and hepatitis and have baseline blood counts, with labs such as lipids and liver enzymes monitored afterward. Live vaccines should be avoided, so immunizations are reviewed first. Common side effects in the trials included headache, acne, upper respiratory infections, and elevated creatine phosphokinase (FDA labels). None of the three is meant to be combined with other JAK inhibitors, biologic immunomodulators, cyclosporine, or other potent immunosuppressants.

Topical JAK inhibitors and other emerging options

A JAK inhibitor cream sounds appealing, but the evidence has not supported it. In a randomized Phase 2 trial, 1.5% ruxolitinib cream performed no better than a vehicle cream for alopecia areata, with 5 of 39 patients reaching the response threshold in each group (Olsen et al., 2020). No topical JAK inhibitor is FDA-approved for alopecia areata. Older oral options such as prednisone, methotrexate, and cyclosporine are still sometimes used (AAD), and research into additional targeted therapies continues. For eyelash loss, bimatoprost is FDA-approved to help lashes grow longer (AAD).

Who is a candidate for JAK inhibitors and who is not

A dermatologist will usually consider a JAK inhibitor when:

• Hair loss is extensive, rapidly progressing, or includes totalis or universalis.
• Injections and topical treatments have not worked or are not practical.
• Age falls within the label (12 and older for ritlecitinib, adults for baricitinib and deuruxolitinib).

Extra caution, or a different plan, is warranted for people with active or chronic infections, untreated latent tuberculosis, a history of blood clots, heart attack, stroke, or cancer, and for current or past smokers. Pregnancy, plans for pregnancy, and breastfeeding also need to be discussed, since breastfeeding is not recommended on ritlecitinib or deuruxolitinib.

Cost, insurance, and specialty pharmacy approvals

Oral JAK inhibitors are high-cost specialty medications, and coverage varies widely by plan. Many insurers require prior authorization with documentation of severity, such as the SALT score and photographs, and sometimes proof that other treatments were tried first. Approval can take weeks and may run through a specialty pharmacy. Manufacturer copay programs may help some commercially insured patients. Your plan determines what your coverage requires, and our post on whether dermatology services are covered by insurance explains the general picture.

How we approach alopecia areata at Bayou City Dermatology

Our hair loss treatment process starts with diagnosis: a focused history, an examination of the hair and follicles, and, when needed, a scalp biopsy and blood work. Once alopecia areata is confirmed and its severity documented, we match treatment to the extent of disease, your age, your health history, and your goals, from injections and topical medications for limited patches to a discussion of oral options for severe disease. Because the condition is chronic, we plan for follow-up rather than a single visit. You can read more about our clinical dermatology services.

When to see a dermatologist in Houston

Book a visit if you notice a smooth, round bald patch, patches that multiply or merge, loss of eyebrows, eyelashes, or beard hair, or any sudden hair loss you cannot explain. Limited patches are simpler to treat than extensive disease, and some look-alike conditions scar permanently if left untreated.

Frequently asked questions

How fast do JAK inhibitors regrow hair?

Regrowth is gradual. The trials measured their main results at 24 weeks for ritlecitinib and deuruxolitinib and at 36 weeks for baricitinib, and regrowth continued to build over that time. Most patients should expect to wait several months before judging whether the medicine is working.

Do you have to stay on JAK inhibitors forever?

The trials studied continuous daily treatment, and these medicines manage the disease rather than cure it. In one baricitinib study, 98% of responders who stayed on 4 mg kept their response at 76 weeks, compared with 75% of those who stepped down to 2 mg. Whether and how to taper is an individual decision made with your dermatologist.

Can alopecia areata come back after treatment?

Yes. The AAD notes that alopecia areata can come and go, and that many people relapse within a year of regrowing their hair.

Is alopecia areata the same as alopecia universalis or totalis?

They are forms of the same condition. Alopecia totalis is loss of all scalp hair, and alopecia universalis is loss of all scalp and body hair. Patients with totalis and universalis were included in the JAK inhibitor trials, though response rates were lower with more extensive hair loss.

Are JAK inhibitors safe long-term?

They carry an FDA boxed warning for serious infections, mortality, malignancy, major cardiovascular events, and blood clots, based largely on data from another JAK inhibitor in older adults with rheumatoid arthritis. Long-term data in alopecia areata are still accumulating, so screening, monitoring, and your personal risk factors guide the decision.

Book a hair loss consultation

Alopecia areata is unpredictable, but it is treatable. Book a hair loss consultation at Bayou City Dermatology to confirm the diagnosis, measure the extent of your hair loss, and talk through which treatments fit your health history and goals.

References

1. American Academy of Dermatology. Alopecia areata: diagnosis and treatment. Accessed October 2026. aad.org
2. American Academy of Dermatology. Alopecia areata: overview. Accessed October 2026. aad.org
3. U.S. Food and Drug Administration. Olumiant (baricitinib) prescribing information, revised June 2026. accessdata.fda.gov
4. U.S. Food and Drug Administration. Litfulo (ritlecitinib) prescribing information, revised June 2026. accessdata.fda.gov
5. U.S. Food and Drug Administration. Leqselvi (deuruxolitinib) prescribing information, revised June 2026. accessdata.fda.gov
6. U.S. Food and Drug Administration. Olumiant (baricitinib) supplemental approval letter for alopecia areata, June 2022. accessdata.fda.gov
7. Pfizer. FDA approves Pfizer's Litfulo (ritlecitinib) for adults and adolescents with severe alopecia areata. June 23, 2023. pfizer.com
8. Olsen EA, et al. Ruxolitinib cream for the treatment of patients with alopecia areata: a 2-part, double-blind, randomized, vehicle-controlled phase 2 study. J Am Acad Dermatol. 2020;82(2):412-419. pubmed.ncbi.nlm.nih.gov
9. Ishida W, Makino T, Shimizu T. Severe hair loss of the scalp due to a hair dye containing para phenylenediamine. ISRN Dermatol. 2011;2011:947284. pmc.ncbi.nlm.nih.gov